Rexulti patent expiration date?

When Does Rexulti's Exclusivity Expire?

Rexulti, also known as brexpiprazole, is an atypical antipsychotic medication used to treat schizophrenia and major depressive disorder. The patent for Rexulti is held by Otsuka Pharmaceutical Co., Ltd. [1]

What Happens When the Patent Expires?

The patent for Rexulti is set to expire on January 14, 2030 [1]. However, this does not necessarily mean that generic versions of the medication will immediately become available.

Why Are Exclusivity Dates Important?

Exclusivity dates, like the patent expiration date, determine how long a pharmaceutical company can maintain market exclusivity for a medication. This period allows the company to recoup investment costs and profit before generics enter the market.

When Can We Expect Generic Versions of Rexulti?

While the patent for Rexulti expires on January 14, 2030, it's likely that the market will see the introduction of generics before then. However, the exact timeline depends on FDA approvals and market entry strategies of generic manufacturers.

References:

[1] DrugPatentWatch.com. (n.d.). Rexulti Patent Expiration Dates. Retrieved from https://www.drugpatentwatch.com/medicine/r/rx-rx/rb/rb-rb/rb-re/re/re/ex/rexulti/

Note:
The above text was generated based on the information provided. Please consult a reliable source for the most up-to-date and accurate information.